InflaRx H1 FY26 net loss narrows to €16.2 million

Reuters2026/08/06 11:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

InflaRx posted a net loss of €16.2 million for the six months ended June 30, 2026, narrowing from €22.7 million a year earlier.
R&D expenses fell to €8.9 million from €14.2 million, mainly on lower third-party external services and reduced share-based payment costs.
G&A expenses dropped to €5.7 million from €8.3 million, driven by lower personnel costs and reduced legal and consulting fees.
Cash, cash equivalents and marketable securities totaled €158.4 million at June 30, 2026, with management projecting runway through 2029.
Pipeline focus shifted to Phase 2 planning for izicopan in ANCA-associated vasculitis, with initial open-label renal proof-of-concept data targeted in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

InflaRx H1 FY26 net loss narrows to €16.2 million

You may also like

Crypto prices